ClinicalTrials.gg
CompletedNCT07707258RMZ-OLI-ENDOUpdated Nov 3, 2026

Remimazolam Combined With Oliceridine for Sedation in Elderly Patients Undergoing Gastrointestinal Endoscopy

An interventional study of Remimazolam Tosilate for Injection and Oliceridine Fumarate in Sedation and Gastrointestinal Endoscopy, sponsored by Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine. Completed at 1 site in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment

Updated Nov 3, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 96 studies in Hypoxia with a site in China — 43 open to participants now, 44 under way, none of them phase 3. Hypoxia · China.

Enrollment
38th of 78
240 · median 240
Started
2026
with 17 others
No phase
63 of 96
31 open now
Registered
87th of 96
by date

Among the 96 studies in Hypoxia with a site in China, this one is the 38th largest by enrollment of the 78 interventional ones that give a count, is one of 18 that started in 2026, is one of 63 with no phase, and was the 87th registered.

Hypoxia

1,078 studies on the registry are indexed under Hypoxia; 214 are open to participants now.

Browse Hypoxia studies →

Open to participants now

43 of the 96 studies in Hypoxia with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 126 Hypoxia studies recruiting now, 53 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Hypoxia with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the sedative efficacy and safety of remimazolam combined with oliceridine in elderly patients undergoing painless gastrointestinal endoscopy. Elderly patients often face higher risks of respiratory and hemodynamic depression during clinical sedation. This trial will investigate whether the combination of remimazolam and oliceridine can provide stable sedation, maintain stable vital signs, and reduce the incidence of adverse events such as hypoxemia and postoperative cognitive fluctuation in this vulnerable population.

Read the detailed description

This is a clinical study conducted at the Baoshan Branch of Renji Hospital, Shanghai Jiao Tong University School of Medicine. The study will strictly adhere to ethical guidelines, and all research activities will be carried out after receiving full approval from the Ethics Committee.

Elderly participants will be enrolled based on predefined inclusion criteria with comprehensive vulnerability assessments. During the gastrointestinal endoscopy procedure, vital signs, particularly oxygen saturation (SpO2) and its duration of depression, will be monitored closely. To address potential educational bias in cognitive assessments, the study will utilize the Mini-Mental State Examination (MMSE) stratified by years of education alongside the Montreal Cognitive Assessment (MoCA) to comprehensively evaluate postoperative cognitive outcomes. Follow-up assessments will be systematically conducted at designated time points (e.g., 1 week, 1 month, 3 months, and 6 months) post-procedure.

03

Conditions studied

  • Sedation
  • Gastrointestinal Endoscopy

Browse trials for

Keywords

  • Remimazolam
  • Oliceridine
  • Older Adults
  • Painless Gastrointestinal Endoscopy
  • Procedural Sedation
  • Hypoxemia
04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Elderly individuals scheduled to undergo painless gastrointestinal endoscopy.
  2. Age between 65 and 80 years.
  3. (BMI) between 18 and 30 kg/m².
  4. (ASA) physical status I-III (ASA III patients eligible only with mild-to-moderate dysfunction of a single organ system, without severe organ failure, and considered able to tolerate the procedure).
  5. Fried frailty phenotype score \< 3.
  6. (MMSE) score ≥ 27.
  7. Provision of written by the patient or legal representative.

Exclusion criteria

Exclusion Criteria:

  1. Allergy or to remimazolam, oliceridine, or sufentanil.
  2. Liver or renal failure ( class C or \< 30 mL/min).
  3. Systemic infection, , coagulation disorder, upper gastrointestinal bleeding, or intestinal obstruction.
  4. History of opioid dependence or long-term use of psychotropic drugs.
  5. Difficult airway or severe respiratory dysfunction.
  6. Cognitive impairment, psychiatric disease, or inability to cooperate with assessment.
  7. (NYHA) functional class III or higher[cite: 3].
  8. Fried frailty phenotype score ≥ 3.
  9. Use of sedative or analgesic drugs within 24 hours before enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Remimazolam + Oliceridine Group

    Patients in this group will receive a combination of remimazolam and oliceridine for sedation during painless gastrointestinal endoscopy. Remimazolam will be administered intravenously for induction and maintenance of sedation, titrated to achieve an appropriate depth of anesthesia. Oliceridine will be administered intravenously to provide stable analgesic cooperation and reduce sedation-related adverse events.

    Drug: Remimazolam Tosilate for Injection · Drug: Oliceridine Fumarate

  • Active comparator
    Active Control Group

    Patients in this group will receive standard remimazolam monotherapy (or remimazolam combined with traditional opioids) for sedation during painless gastrointestinal endoscopy. remimazolam will be administered intravenously to induce and maintain the sedation required for the endoscopic procedure, adhering to standard clinical anesthesia management protocols.

    Drug: Remimazolam Tosilate for Injection

Interventions

  • Administered intravenously for sedation induction and maintenance during gastrointestinal endoscopy. The dosage will be titrated according to the patient's sedation depth and clinical response.

    Also known as: Remimazolam Tosilate, Remimazolam

  • DrugOliceridine Fumarate

    Administered intravenously before or during the procedure to provide stable analgesic cooperation and optimize procedural sedation quality in elderly patients.

    Also known as: Oliceridine

06

What researchers measure

Primary outcomes

  1. Incidence of hypoxemia

    The proportion of participants who experience at least one episode of hypoxemia during procedural sedation for gastrointestinal endoscopy. Hypoxemia is defined as peripheral oxygen saturation (SpO₂) \< 90%. SpO₂ will be continuously monitored throughout the observation period.

    Time frame: From initiation of sedation induction to completion of the gastrointestinal endoscopic procedure, approximately 30 minutes.

Secondary outcomes

  1. Incidence of Hypotension

    The proportion of participants who experience at least one episode of hypotension during procedural sedation. Hypotension is defined as a decrease in mean arterial pressure (MAP) of more than 20% from the pre-induction baseline. MAP will be recorded at baseline and monitored throughout the observation period.

    Time frame: From the pre-induction baseline assessment to transfer to the post-anesthesia care unit, up to 1 hour.

  2. Sedation success rate

    The proportion of patients who achieve a satisfactory sedation depth (MOAA/S score ≤ 1) without the need for rescue sedative medications.

    Time frame: From the start of sedation induction to the completion of the endoscopic procedure

07

Study locations

1 site
  • Shanghai Baoshan District Dachang Hospital (Renji Hospital Baoshan Branch)
    Shanghai, Shanghai Municipality 200444, China
08

References and documents

Individual participant data

Plan to share: No — Due to the inclusion of sensitive clinical and private information of elderly patients, full individual participant data (IPD) cannot be made publicly available as it was not explicitly authorized in the patient informed consent. To protect patient privacy and ensuring data security, the raw IPD will not be shared on public platforms. De-identified data may be available from the corresponding author upon reasonable academic request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Aug 2026, 1 month.

Of 323 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 1 month is below that.

Counting every sponsor, half of 353 studies reached it within 12 months; a quarter within 4 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Sep 2026 → Aug 2026 and completion Dec 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2026
First posted
Jul 16, 2026
StartActual
Jul 17, 2026
Primary completionActual
Aug 30, 2026was Sep 2026
CompletionActual
Aug 30, 2026was Dec 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 3, 2026
Primary completion
Sep 1, 2026→Aug 30, 2026 (actual)
Nov 3, 2026
Study completion
Dec 1, 2026→Aug 30, 2026 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Recruiting→Completed
    Primary completion Sep 1, 2026→Aug 30, 2026 (now actual)
    Study completion Dec 1, 2026→Aug 30, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07707258
Lead sponsor
Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jul 17, 2026
Primary completion
Aug 30, 2026
Completion
Aug 30, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion